International Journal of Medical Science and Clinical Invention 8(4): 5339-5380, 2021
DOI:10.18535/ijmsci/v08i4.05
e-ISSN:2348-991X, p-ISSN: 2454-9576

Leveraging Digital Twins for Root Cause Analysis in Complex Medical Device Manufacturing

Binitkumar M Vaghani

MS in Mechanical Engineering, United States

Abstract
Medical device manufacturing is a highly complex and regulated industry where product failures can directly impact patient safety and public health. Ensuring reliability requires effective quality management strategies, with root cause analysis (RCA) serving as a critical tool for identifying and eliminating sources of defects. However, conventional RCA approaches often depend on retrospective data reviews, manual inspections, and expert judgment, which can be slow, reactive, and prone to subjectivity. As medical devices grow more advanced and interconnected, these traditional methods are no longer sufficient to meet the increasing demands for efficiency, accuracy, and compliance.

Digital Twin (DT) technology has emerged as a promising solution by creating real-time virtual representations of physical devices, systems, and processes. By integrating IoT-enabled data streams, predictive simulations, and advanced analytics, DTs allow continuous monitoring, rapid anomaly detection, and predictive fault modeling. Unlike static approaches, digital twins support proactive RCA by simulating potential failure scenarios and enabling manufacturers to test corrective measures before implementation. This not only improves the speed and precision of problem-solving but also ensures alignment with stringent regulatory frameworks such as ISO 13485 and EN 62304.

This paper investigates how digital twins can be leveraged for RCA in complex medical device manufacturing. It compares traditional RCA methods with DT-driven approaches, highlights their impact on compliance and safety, and demonstrates how DT adoption reduces risks, improves traceability, and enhances operational resilience. The findings suggest that integrating DTs into RCA processes will transform quality management practices, providing a foundation for future AI-augmented models that advance predictive and prescriptive fault analysis. Ultimately, DT-enabled RCA has the potential to redefine reliability and patient safety in the medical device sector.

Keywords: Digital Twin, Root Cause Analysis, Medical Device Manufacturing, Quality Management, Regulatory Compliance, Predictive Analytics, Industry 4.0.

1. Introduction

1.1 Background on Medical Device Complexity and Risk Factors

The medical device manufacturing sector represents one of the most complex and highly regulated industries in the world. Unlike other manufacturing domains, where failures may result in financial losses or operational downtime, failures in medical devices can directly affect human health, safety, and even survival. This inherently high-stakes environment places a premium on quality management, reliability, and traceability throughout the product lifecycle. Standards such as ISO 13485 require manufacturers to establish rigorous quality management systems that ensure design control, risk mitigation, and end-to-end product traceability (Bos 2018).

Medical devices often integrate diverse components—including electronics, embedded software, biocompatible materials, and precision-manufactured hardware—each of which presents unique failure modes. The increasing complexity is further compounded by the global nature of supply chains, where outsourcing of raw materials and specialized parts introduces additional risks of inconsistency and variability. For example, a malfunction in a cardiovascular stent, a calibration error in a diagnostic imaging machine, or a defect in a surgical robot may have life-threatening consequences. Beyond clinical risks, such failures also result in regulatory penalties, recalls, and reputational damage, underscoring the critical role of robust quality management practices.

The lifecycle of medical devices—from ideation and prototyping through production, deployment, and post-market surveillance—demands continuous monitoring and failure analysis. This is particularly important as devices become increasingly software-driven, with standards such as IEC 62304/EN 62304 governing software lifecycle processes. In this context, root cause analysis (RCA) emerges as a vital practice to ensure that failures or deviations are systematically identified, their underlying causes isolated, and corrective or preventive actions implemented. However, as devices become more interconnected and functionally sophisticated, the limitations of conventional RCA methods become more apparent.

1.2 Limitations of Traditional RCA Methods in Safety-Critical Industries

Traditional RCA has long been a cornerstone of industrial problem-solving, employing methodologies such as Ishikawa (fishbone) diagrams, fault tree analysis, and the “5 Whys” technique. While these methods have proven effective in relatively stable or low-complexity manufacturing systems, they struggle to keep pace with the dynamic, multi-layered, and safety-critical environment of medical device manufacturing. According to Zema et al. (2015), conventional RCA is largely reactive, meaning it is initiated only after a failure has already occurred, often with significant consequences. This time lag between occurrence and detection prolongs downtime, increases cost, and, in the medical domain, poses potential risks to patients.

A second limitation lies in the subjectivity of human expertise. Traditional RCA often depends heavily on the knowledge and interpretation of engineers and quality assurance personnel. While expertise is invaluable, it can introduce variability, cognitive bias, and gaps in consistency, especially when multiple stakeholders across disciplines are involved. This problem is exacerbated in medical device contexts where failures may span hardware, software, and human factors, making it difficult for a single RCA approach to capture the full range of interacting variables.

Another weakness of traditional RCA is the challenge of scalability and traceability. As manufacturing systems become digitized and generate vast amounts of process and quality-control data, manually analyzing logs or inspection records becomes impractical. In highly regulated environments, regulators such as the FDA require manufacturers not only to identify the root cause of failures but also to demonstrate transparent and verifiable evidence of the corrective process. Traditional RCA tools lack built-in mechanisms to generate such regulatory-grade documentation, leaving compliance gaps that can delay approvals or trigger penalties. Thus, while RCA remains indispensable, its conventional execution is increasingly inadequate for the safety-critical, data-intensive world of modern medical device manufacturing.

1.3 Emergence of Digital Twin Technology as a Game Changer

The digital twin (DT) concept, first formally introduced by Grieves (2014), represents a paradigm shift in manufacturing and systems engineering. Defined as a virtual representation of a physical asset that remains dynamically linked through real-time data, DTs create a bi-directional information flow between the physical and digital domains. Boschert and Rosen (2016) emphasized that the strength of DT lies not only in its ability to mirror physical systems but also in its capacity to simulate, predict, and optimize performance under different scenarios.

In the context of RCA, DTs offer transformative capabilities that overcome the limitations of traditional methods. By continuously aggregating data from IoT-enabled sensors, production equipment, and operational software, DTs provide a holistic, real-time picture of device performance. When anomalies occur, the DT can simulate possible causes, evaluate alternative scenarios, and rank hypotheses based on likelihood. This predictive and prescriptive ability ensures that corrective actions can be evaluated virtually before implementation, reducing risk, downtime, and cost.

The value of DTs extends beyond fault detection and extends into compliance assurance. Regulatory standards demand rigorous documentation of processes, decisions, and outcomes. DT systems can generate automated audit trails, recording every parameter adjustment, simulation result, and corrective step, thereby satisfying regulators such as the FDA or notified bodies in Europe. Moreover, DT integration with cyber–physical systems, AI, and advanced analytics enhances not only the speed but also the accuracy of RCA, making them particularly suited for the safety-critical medical device sector.

For example, in manufacturing a pacemaker or blood pump, a DT can continuously monitor vibration, thermal, and performance signals, comparing them to virtual models that account for ideal operating conditions. Deviations can be flagged immediately, and root causes such as component wear, software lag, or assembly inconsistencies can be isolated in silico before impacting patient outcomes. This represents a shift from reactive RCA to proactive and predictive RCA, positioning DTs as indispensable tools for the future of medical device quality management.

1.4 Research Objectives and Scope – Focus on DT-Driven RCA for Medical Devices

Given the above context, this research sets out to explore the question: How can digital twin technology be leveraged to enhance root cause analysis in complex medical device manufacturing? The objectives are fourfold:

- Critically examine the shortcomings of traditional RCA methods in medical device contexts, particularly their lack of real-time capability, scalability, and regulatory traceability (Zema et al. 2015).
- Investigate how DTs can transform RCA by providing real-time anomaly detection, predictive simulation of potential causes, and automated documentation for compliance (Grieves 2014; Boschert & Rosen 2016).
- Evaluate regulatory alignment, focusing on how DT-enabled RCA can support compliance with ISO 13485 and EN 62304, while meeting FDA's requirements for computational model credibility (Bos 2018; Morrison et al. 2019).
- Propose a conceptual framework for DT-enabled RCA tailored to the complexities of medical device manufacturing, with illustrative comparisons to traditional methods.

The scope of this study is deliberately focused on the medical device sector, given its unique combination of product complexity, regulatory intensity, and patient safety imperatives. While DTs are increasingly applied in broader manufacturing domains such as automotive or aerospace, their potential in medical device manufacturing remains underexplored and requires context-specific analysis. By synthesizing insights from digital twin literature, regulatory frameworks, and RCA methodologies, this research aims to contribute to both academic discourse and practical implementation strategies. Ultimately, the study underscores the promise of DT-driven RCA not just as a technological upgrade but as a necessary evolution in ensuring the safety, reliability, and compliance of medical devices in the era of Industry 4.0.

2. Literature Review

Digital Twin (DT) technology has emerged as a cornerstone of Industry 4.0, providing a robust mechanism for mirroring physical assets, processes, and systems in the digital space. Its applications extend from general manufacturing to highly specialized industries such as aerospace, energy, and healthcare. In medical device manufacturing, DTs are gaining recognition for their potential to transform root cause analysis (RCA) by leveraging real-time data, simulations, and regulatory frameworks. This section reviews the conceptual foundations, general manufacturing applications, smart manufacturing implementations for RCA, and the regulatory and validation requirements essential for medical device adoption.

2.1 Digital Twin Conceptual Foundations

The concept of the digital twin can be traced back to the early 2000s but was formally articulated by Grieves (2014), who defined it as a virtual factory replication. This vision proposed that every physical entity could be paired with a digital counterpart capable of reflecting its current state, historical data, and predicted future behavior. Grieves emphasized the use of DTs in product lifecycle management, suggesting that such integration could reduce errors, shorten development cycles, and improve product quality.

Boschert and Rosen (2016) advanced this concept by focusing on the simulation aspect of DTs. They described DTs as dynamic digital entities that continuously synchronize with their physical counterparts, evolving through data acquisition and advanced modeling. According to their framework, DTs support real-time monitoring, predictive analytics, and scenario-based decision-making, allowing manufacturers to identify root causes of issues before they escalate into failures.

A critical step in clarifying DTs came from Kritzinger et al. (2018), who classified digital representations into three categories:

- Digital Model: A static virtual copy without connection to the physical system.
- Digital Shadow: A representation with one-way data flow from the physical to the digital domain.
- Digital Twin: A full bi-directional interaction where changes in either domain affect the other.

This classification is essential in distinguishing between basic simulation tools and true digital twins. For RCA, the full DT—capable of real-time synchronization and two-way data integration—is the most relevant, as it allows not only analysis of past failures but also prediction and proactive mitigation.

Together, these studies underscore the evolution of DTs from conceptual virtual models to real-time, interactive systems, setting the stage for advanced applications in manufacturing and RCA.

2.2 Applications of DT in General Manufacturing

The adoption of DTs in general manufacturing illustrates their transformative impact across multiple stages of the production lifecycle.

Lim, Zheng, and Chen (2020) conducted a state-of-the-art survey, highlighting DTs as enablers of end-to-end product lifecycle management. They argued that DTs connect product design, production, operation, and recycling stages, thereby providing a unified platform for decision-making. In manufacturing, this capability enhances predictive maintenance, quality monitoring, and supply chain optimization, all of which contribute indirectly to RCA by reducing uncertainties in system performance.

Zhang et al. (2019) further expanded DT applications by introducing a reconfigurable modeling approach. Their research focused on flexible manufacturing systems, where DTs were employed to dynamically reconfigure production lines in response to disturbances or changes in demand. For instance, if a defect or bottleneck was detected, the DT model could simulate alternative configurations in real time, enabling faster problem resolution. Such flexibility is highly relevant to medical device manufacturing, which often requires small batch customization, rapid adaptation to regulatory changes, and strict process traceability.

These contributions demonstrate that DTs go beyond simple monitoring to become decision-support systems that can reconfigure, optimize, and validate manufacturing processes. In the context of medical devices, such adaptability is invaluable for RCA because product quality and compliance must be ensured throughout the entire lifecycle.

2.3 DTs for RCA in Smart Manufacturing

A central strength of DTs lies in their integration with IoT, big data, and advanced analytics to improve RCA. Traditional RCA often relies on human expertise and post-event analysis, which can delay corrective actions. DTs provide a data-driven, automated approach, reducing subjectivity and enhancing accuracy.

Papacharalampopoulos et al. (2020) presented a landmark study in which a DT was developed to automate RCA for production alarms. By leveraging IoT-based KPIs, the DT was able to systematically capture deviations, identify correlations, and suggest potential causes without requiring manual intervention. This shift toward automated RCA reduces downtime and ensures that manufacturing systems can self-diagnose in real time.

Tao et al. (2018) investigated the role of DTs in prognostics and health management (PHM). Their work demonstrated how DTs could be used to forecast failures by simulating equipment degradation patterns. This predictive capability supports proactive RCA, where the system not only identifies existing failures but also anticipates future ones, allowing manufacturers to implement preventive measures before critical failures occur.

Ma et al. (2019) extended the application of DTs to human–machine interaction. They argued that DTs create collaborative platforms where human expertise is combined with digital insights. Engineers can interact with DTs to visualize failure scenarios, test hypotheses, and validate corrective actions. This enhances decision-making transparency, a crucial factor in regulated industries like medical devices, where auditability and human oversight are mandatory.

Taken together, these studies confirm that DTs transform RCA from a reactive, human-centric process into a proactive, automated, and collaborative framework that integrates predictive analytics, simulation, and human expertise.

2.4 Regulatory and Validation Context

For DTs to be effective in medical device manufacturing, they must align with stringent regulatory frameworks and validation standards that govern safety, quality, and compliance.

ISO 13485 establishes a global quality management system for medical devices, emphasizing risk management, process control, and documentation (Bos 2018). In the context of RCA, DTs can enhance compliance by automatically logging data, generating traceable records of failures, and demonstrating corrective actions in line with ISO standards.

EN 62304 specifically addresses medical device software lifecycle processes, mandating rigorous verification and validation (V&V) (Höss et al. 2014). Since DTs rely heavily on computational models and embedded software, compliance with EN 62304 is essential to ensure that DT-driven RCA processes are recognized as valid by regulatory bodies.

In the United States, the FDA has increasingly emphasized credibility evidence for computational models. Morrison et al. (2019) developed a risk-based framework for assessing the credibility of such models, focusing on their intended use, associated risks, and supporting evidence. Similarly, Parvinian et al. (2019) examined the validation of computational patient models in critical care devices, demonstrating that regulators require not only technical accuracy but also transparent documentation of assumptions, limitations, and risks. These frameworks are directly applicable to DTs used in RCA, which must prove both reliability and regulatory trustworthiness.

Finally, Freitas (2020) addressed the importance of verification, validation, and uncertainty quantification (VVUQ) in computational modeling. He argued that without standardized methods for assessing uncertainty and credibility, computational models—including DTs—risk being dismissed as untrustworthy in regulated environments. This underscores the need for rigorous, standardized V&V protocols if DTs are to be widely adopted in medical device RCA.

3. Conceptual Framework

The conceptual framework underpinning this study explains how Digital Twin (DT) technology can be systematically embedded into the Root Cause Analysis (RCA) process for complex medical device manufacturing. It provides a structured lens through which the integration of real-time data acquisition, advanced simulation, regulatory compliance, and corrective decision-making can be understood. The framework consists of three interrelated dimensions: (i) the proposed DT-enabled RCA process flow, (ii) the analytical dimensions of performance and credibility, and (iii) the theoretical alignment with cyber–physical systems (CPS) and Industry 4.0 paradigms.

3.1 Proposed DT-Enabled RCA Process Flow

Root Cause Analysis in medical device manufacturing traditionally involves retrospective data examination, interviews with technical teams, manual review of production logs, and hypothesis-driven testing (Zema et al., 2015). While such methods have produced acceptable results, their dependence on manual processes often causes delays in identifying the root cause of device failures. Furthermore, these methods are reactive, meaning that failures must occur before corrective actions can be initiated. The introduction of DT technology transforms RCA into a proactive and predictive process by embedding continuous monitoring, simulation-based testing, and regulatory compliance into a unified digital environment (Grieves, 2014; Boschert & Rosen, 2016; Tao et al., 2019).

The proposed DT-enabled RCA process flow consists of six sequential but interdependent stages:

Step 1: IoT Data Capture

Medical devices and their manufacturing processes are now equipped with Internet of Things (IoT) sensors that monitor critical parameters such as mechanical stress, vibration, electrical currents, temperature, humidity, and sterility indicators. These data streams provide real-time visibility of system states across assembly lines, sterilization chambers, packaging units, and embedded software performance (Papacharalampopoulos et al., 2020). By reducing reliance on retrospective logbooks, IoT systems capture subtle deviations that may serve as early warning signals of systemic failure.

Step 2: Digital Twin Synchronization

Captured IoT data are ingested into a Digital Twin environment, which serves as a continuously updated virtual model of the physical asset or process (Boschert & Rosen, 2016). Synchronization ensures that the DT mirrors the real-world system in near real time. For example, in an insulin pump production line, a DT may reflect real-world needle calibration deviations, enabling engineers to observe how micro-level defects cascade into macro-level performance issues. This synchronization forms the nervous system of RCA, ensuring dynamic visibility of the manufacturing process.

Step 3: Anomaly Detection

Once synchronized, the DT environment applies machine learning (ML) algorithms, statistical process control (SPC), and pattern recognition techniques to detect deviations from normal operating ranges (Morrison et al., 2019). For example, if a blood pump exhibits abnormal turbulence signatures in its fluid dynamic data, anomaly detection within the DT highlights the exact time, location, and conditions under which the irregularity arose. This predictive anomaly detection stage prevents catastrophic failures by identifying early deviations that traditional RCA methods may overlook.

Step 4: Root Cause Hypothesis Simulation

In conventional RCA, hypotheses are tested on physical systems, which is time-consuming, costly, and sometimes unsafe. DTs replace this reactive approach with virtual hypothesis testing, allowing engineers to simulate multiple “what-if” scenarios. For instance, if a stent-coating defect is detected, simulations within the DT can evaluate whether the defect arose from raw material contamination, machine calibration error, or operator handling (Tao et al., 2018). Multiple hypotheses can be tested in silico, significantly reducing the trial-and-error burden on physical devices.

Step 5: Regulatory Compliance Check

Medical device manufacturing operates under stringent quality management and regulatory standards, including ISO 13485 for quality systems (Bos, 2018), EN 62304 for medical device software development (Höss et al., 2014), and FDA guidance on computational model validation (Parvinian et al., 2019; Morrison et al., 2019). Within the DT framework, compliance checkpoints are embedded into RCA, producing automatically generated traceability records, risk assessments, and validation reports (Freitas, 2020). This ensures that RCA outputs are defensible during audits, reducing the compliance burden on manufacturers.

Step 6: Corrective Action

Finally, once validated hypotheses identify the most probable root cause, corrective actions are simulated virtually within the DT before implementation. This stage minimizes unintended consequences, as interventions are tested in a safe virtual environment before being applied to the physical system (Chen et al., 2020). Corrective action outcomes—such as adjusted process parameters, updated sterilization cycles, or modified calibration routines—are deployed with confidence, backed by predictive simulations.

Graph 1 (Flowchart):

A flowchart illustrating the six stages should:

IoT Data Capture → Digital Twin Synchronization → Anomaly Detection → Root Cause Hypothesis Simulation → Regulatory Compliance Check → Corrective Action.



3.2 Analytical Dimensions

The proposed framework's strength lies in its ability to be evaluated across five analytical dimensions: accuracy, scalability, compliance, credibility, and predictive power. These dimensions also form the criteria by which DT adoption can be assessed in medical device RCA.

Accuracy:

- Traditional RCA depends on expert judgment, which is inherently subjective. By contrast, DT-enabled RCA integrates empirical IoT data and simulation outputs, significantly reducing subjectivity (Papacharalampopoulos et al., 2020). For example, identifying whether a ventilator malfunction originates from its control algorithm or its airflow hardware can be determined precisely using DT simulation accuracy.

Scalability:

- Medical devices are increasingly complex, involving multilayered assemblies, embedded software, and biocompatibility considerations. Traditional RCA cannot feasibly analyze thousands of interacting variables simultaneously. DT systems provide system-wide scalability, allowing RCA to be conducted at component, subsystem, and system levels concurrently (Lim et al., 2020). This is critical for devices like MRI machines or implantable defibrillators, where multiple subsystems interact dynamically.

Compliance:

- Compliance is a non-negotiable requirement in medical device manufacturing. ISO 13485 demands risk-based decision-making and full traceability, while EN 62304 governs software lifecycle processes (Bos, 2018; Höss et al., 2014). DT-enabled RCA provides automated compliance documentation such as electronic Device History Records (eDHRs), which can be directly audited by regulators (Freitas, 2020).

Credibility:

- Regulatory acceptance of DT outcomes depends on the credibility of computational models. Morrison et al. (2019) introduced a risk-based framework for computational model credibility, emphasizing validation, verification, and uncertainty quantification. DT-based RCA can incorporate these frameworks, producing evidence-based corrective actions defensible under regulatory scrutiny.

Predictive Power:

- Perhaps the most transformative dimension is predictive capacity. DTs allow RCA to not only identify existing failures but also predict potential future causes of failure. For instance, DT simulations can forecast how cumulative stress on pacemaker leads may cause long-term degradation, enabling pre-emptive recalls or design modifications (Tao et al., 2018).

3.3 Theoretical Alignment

The framework aligns with the broader theories of cyber–physical systems (CPS) and the Industry 4.0 paradigm.

Digital Twin and CPS Integration:

- DTs are a practical manifestation of CPS, where physical assets and their digital counterparts co-exist in a closed-loop system (Rosen et al., 2015). This integration enables seamless RCA by bridging the physical and digital domains.

Industry 4.0 Alignment:

- Industry 4.0 emphasizes connectivity, interoperability, and data-driven automation. DT-enabled RCA is a direct application of these principles, using IoT, artificial intelligence, and cloud platforms to ensure smart, resilient, and traceable manufacturing (Tao et al., 2019).

Human–Machine Collaboration:

- DTs facilitate a collaborative framework where engineers, operators, and regulators interact with virtual models. Human expertise interprets simulation outputs, while the DT provides data-driven insights (Ma et al., 2019). This socio-technical synergy enhances RCA decision-making.

Regulatory–Technological Convergence:

- Finally, the alignment highlights the convergence of technology and regulation. By embedding compliance into the DT process, the framework acknowledges the dual imperatives of innovation and regulatory oversight that define medical device manufacturing (Viceconti et al., 2016).

4. Methodology

The methodology for this research paper is designed to provide a structured, transparent, and comprehensive approach to understanding how Digital Twin (DT) technology can be leveraged to strengthen root cause analysis (RCA) in the complex environment of medical device manufacturing. Given the novelty of applying DTs specifically to RCA within a regulated industry, this study adopts a conceptual comparative framework, supported by peer-reviewed literature, regulatory standards, and real-world case studies. The methodology comprises three main components: (i) the research approach, (ii) the sources of data, and (iii) the evaluation parameters through which comparative analysis is conducted.

4.1 Research Approach

This research utilizes a conceptual comparative framework rather than a purely empirical or experimental design. The rationale for this choice is threefold:

Emerging Field and Limited Empirical Data

- Digital Twin integration into RCA for medical device manufacturing is still in its early stages. Large-scale empirical datasets and long-term industrial benchmarks are scarce (Grieves, 2014; Boschert & Rosen, 2016).
- Thus, a conceptual synthesis of existing literature provides a rigorous way to consolidate knowledge and draw meaningful insights for academic and industrial application.

Suitability for Regulated Environments

- Medical device manufacturing operates under stringent regulatory oversight (Bos, 2018; Höss et al., 2014). A conceptual framework allows alignment with standards such as ISO 13485 and EN 62304, ensuring that proposed DT-enabled RCA models are not only technically feasible but also regulatory-compliant.

Comparative Analysis Strength

- RCA in this context requires a structured comparison between traditional RCA methods (manual, retrospective, reactive) and DT-enabled RCA approaches (predictive, real-time, simulation-driven).
- By comparing these approaches across standardized dimensions, the methodology provides clarity on where DTs add value, what gaps they address, and what regulatory hurdles remain (Papacharalampopoulos et al., 2020; Tao et al., 2018).

The approach is implemented through three sequential stages:

- Stage 1: Literature Synthesis – A systematic review of peer-reviewed works on DT concepts, classifications, and applications in manufacturing and healthcare (Kritzinger et al., 2018; Lim et al., 2020).
- Stage 2: Comparative Mapping – Positioning DT-enabled RCA methods alongside traditional RCA practices to highlight strengths, weaknesses, and alignment with RCA goals.
- Stage 3: Regulatory Integration Analysis – Evaluating how DT-driven RCA can meet global medical device compliance requirements through cross-referencing regulatory standards and validation frameworks (Morrison et al., 2019; Freitas, 2020).

This staged design allows for both academic rigor and practical applicability, ensuring the findings remain relevant for scholars, regulators, and industry practitioners.

4.2 Data Sources

The evidence base for this study is drawn from three interconnected categories:

(i) Academic Literature and Theoretical Foundations

- Origins of DT: Grieves (2014) and Boschert & Rosen (2016) provide foundational definitions of DTs, positioning them as synchronized virtual replicas of physical systems.
- Classification and Reviews: Kritzinger et al. (2018) categorize DT approaches into descriptive, predictive, and prescriptive models, which frame the RCA functions. Lim et al. (2020) provide a state-of-the-art survey across engineering and product lifecycles.
- Application Studies: Tao et al. (2018) and Ma et al. (2019) explore DTs in prognostics, health management, and human–machine collaboration, all of which inform RCA design.

(ii) Regulatory and Standards Frameworks

- ISO 13485: Provides global guidelines for quality management systems in medical devices, emphasizing risk management and traceability (Bos, 2018).
- EN 62304: Establishes software lifecycle standards for medical device reliability and safety (Höss et al., 2014).
- FDA and Validation Standards: Morrison et al. (2019) and Parvinian et al. (2019) provide frameworks for computational model credibility, while Freitas (2020) outlines verification, validation, and uncertainty quantification methodologies.

(iii) Industrial Case Studies and Applied Research

- Automated RCA with DT: Papacharalampopoulos et al. (2020) demonstrate DT-based automated RCA for production alarms using IoT and KPI aggregation.
- Pharmaceutical Parallels: Chen et al. (2020) highlight DT use in pharmaceutical and biopharmaceutical contexts, offering transferable lessons for medical devices.
- In Silico Trials: Viceconti et al. (2016) introduce the concept of computational models for clinical evaluation, a precedent for DT acceptance in regulatory environments.

By combining theoretical, regulatory, and applied perspectives, the data sources provide a triangulated evidence base, ensuring balanced insights into both opportunities and challenges of DT-enabled RCA.

4.3 Evaluation Parameters

To systematically assess the effectiveness of DT-enabled RCA compared to traditional RCA methods, the study adopts five evaluation parameters. These parameters were chosen based on their relevance to both industry performance goals and regulatory expectations:

1. Compliance

- Focuses on how effectively RCA practices meet international regulatory requirements.
- Traditional RCA relies heavily on manual records, while DT systems provide automated traceability, audit-ready logs, and transparent documentation (Bos, 2018; Höss et al., 2014).

2. Speed

- Assesses the time required to detect, analyze, and resolve root causes.
- Traditional RCA is reactive and time-consuming, often conducted post-failure, while DT-enabled RCA leverages real-time monitoring and predictive diagnostics (Papacharalampopoulos et al., 2020; Tao et al., 2018).

3. Accuracy

- Evaluates the reliability of RCA outcomes.
- Traditional methods are prone to subjectivity, whereas DT-enabled RCA employs simulation, data-driven anomaly detection, and model-based validation, increasing diagnostic precision (Ma et al., 2019; Zhang et al., 2019).

4. Transparency

- Examines the visibility and auditability of RCA processes.
- Regulatory inspections require complete and verifiable records. DT frameworks enhance transparency by providing simulation records, dashboards, and digital validation evidence (Freitas, 2020).

5. Adaptability

- Measures the ability of RCA frameworks to adjust to evolving manufacturing processes, technologies, and regulatory updates.
- DTs offer reconfigurability and scalability, enabling firms to remain compliant even as regulatory frameworks evolve (Zhang et al., 2019; Chen et al., 2020).

Table 1: A comparative table contrasting Traditional RCA vs. DT-Enabled RCA across the five parameters (Compliance, Speed, Accuracy, Transparency, Adaptability).

Parameter	**Traditional RCA Characteristics**	**DT-Enabled RCA Characteristics**	**References**
Compliance	Manual records, retrospective audits	Automated traceability, ISO 13485-ready	Bos (2018); Höss et al. (2014)
Speed	Reactive, post-failure	Predictive, real-time, proactive	Tao et al. (2018); Papacharalampopoulos et al. (2020)
Accuracy	Subjective, operator-dependent	Data-driven, simulation-based	Ma et al. (2019); Zhang et al. (2019)
Transparency	Limited documentation, hard to audit	Dashboards, simulation logs, validation	Freitas (2020)

Adaptability	Static, rigid frameworks	Reconfigurable, scalable, future-proof	Chen et al. (2020); Zhang et al. (2019)

5. Results (Illustrative / Expected)

The results presented in this section are conceptual and illustrative, derived from an in-depth synthesis of scholarly literature, regulatory guidelines, and industrial case evidence. They illustrate how Digital Twin (DT) technology can transform Root Cause Analysis (RCA) in complex medical device manufacturing, providing comparative insights into traditional approaches, highlighting domain-specific applications, analyzing adoption trends, and assessing predictive and regulatory credibility dimensions.

5.1 Comparative Analysis of RCA Approaches

Traditional RCA in medical device manufacturing is typically retrospective in nature, relying on historical failure data, manual inspections, and the subjective judgment of domain experts (Zema et al. 2015). These approaches, while foundational, are limited in their ability to handle the increasing complexity of modern devices, where interactions between hardware, embedded software, and production processes create multi-layered failure modes (Bos 2018).

By contrast, DT-enabled RCA leverages real-time IoT data, virtual replicas, and simulation models that continuously synchronize with physical assets (Grieves 2014; Boschert & Rosen 2016). These digital replicas provide a living model of medical devices and their production processes, enabling proactive identification of anomalies, testing of multiple hypotheses virtually, and automatic generation of compliance-ready documentation (Qi et al. 2018; Papacharalampopoulos et al. 2020).

The differences are captured in Table 2, which demonstrates the clear superiority of DT-based RCA across five dimensions: data sources, accuracy, speed, compliance, and scalability.

Table 2: Traditional RCA vs. Digital Twin–Enabled RCA

Criteria	Traditional RCA	Digital Twin–Enabled RCA	References
Data Source	Historical logs, batch records, manual inspections	Real-time IoT sensor streams, synchronized DT models, simulation feedback	Zema et al. 2015; Qi et al. 2018
Accuracy	Moderate; heavily dependent on expert interpretation	High; driven by validated computational models and continuous data updates	Boschert & Rosen 2016; Papacharalampopoulos et al. 2020
Speed	Reactive, post-failure analysis; time-consuming	Proactive and predictive; near real-time anomaly identification	Tao et al. 2019; Ma et al. 2019
Compliance	Manual documentation; prone to errors during audits	Automated traceability aligned with ISO 13485 and EN 62304 requirements	Bos 2018; Höss et al. 2014
Scalability	Limited scalability	Highly scalable; can	Lim et al. 2020; Zhang

	across complex device ecosystems	cover entire production and lifecycle management	et al. 2019

Interpretation:

The comparative analysis demonstrates that DT-enabled RCA offers a quantum leap in both performance and compliance. While traditional RCA remains valuable for post-failure investigations, DTs provide a continuous, predictive layer of RCA that accelerates resolution times and minimizes costly recalls or regulatory penalties.

5.2 Applications of DT in Medical Device Manufacturing

Medical devices must comply with stringent regulatory requirements that demand not only functional safety but also transparent traceability of decision-making during RCA processes. DT technology provides unique opportunities to align real-time operational intelligence with frameworks such as ISO 13485 (quality management systems) and EN 62304 (medical device software lifecycle safety).

Applications extend from software validation to production quality alarms and in silico clinical simulations. By embedding DT into RCA processes, manufacturers can achieve automated regulatory reporting, risk-based assessments, and lifecycle optimization that is otherwise unattainable through manual methods (Papacharalampopoulos et al. 2020; Morrison et al. 2019).

Table 3: DT Applications Mapped to Regulatory Standards

Application Area	**DT Role in RCA**	**Regulatory Standard Alignment**	**References**
Software Validation	Simulation-driven verification of embedded software modules	EN 62304 (software lifecycle safety)	Höss et al. 2014; Laukkarinen et al. 2017
Production Alarm Analysis	Automated RCA of alarms based on IoT/KPI aggregation	ISO 13485 (risk management & traceability)	Papacharalampopoulos et al. 2020
Risk-Based Assessment	Computational models provide evidence for safety-critical RCA	FDA’s model credibility framework	Morrison et al. 2019; Parvinian et al. 2019
Lifecycle Optimization	Human–machine DT integration for continuous diagnostics	ISO 13485 (device lifecycle traceability)	Ma et al. 2019
In Silico Trials	Patient-specific simulations for failure risk assessment	FDA/EMA guidelines on in silico evidence	Viceconti et al. 2016

Interpretation:

This mapping shows that DT adoption is not only technologically advantageous but also strategically aligned with regulatory evolution. Regulators are increasingly open to computational evidence, which places DT-driven RCA at the forefront of future compliance pathways.

5.3 Adoption Trends

Despite the promise of DTs, their adoption in medical device manufacturing lags behind other sectors such as automotive, aerospace, and electronics. In these industries, DT implementation is already central to predictive maintenance, performance optimization, and failure diagnosis (Lim et al. 2020). By contrast, in the medical domain, regulatory hesitancy and validation complexity slow adoption (Chen et al. 2020).

Graph 2 (Bar Chart): Adoption of Digital Twin (DT) Across Industry Sectors



Interpretation:

The chart underscores that medical device manufacturing is still in an early adoption stage, but the regulatory acceptance of in silico trials (Viceconti et al. 2016) and computational credibility frameworks suggests an imminent acceleration.

5.4 Predictive Failure Analysis

A defining feature of DT-enabled RCA is its ability to identify latent failure modes before they manifest in physical devices. Traditional RCA detects failures retrospectively, often after non-conformance reports or adverse events, while DTs integrate prognostics and health management (PHM) into the device lifecycle (Tao et al. 2018).

Examples of predictive failure detection include:

- Identifying material fatigue in surgical implants through simulation stress testing.
- Predicting software anomalies in infusion pumps via DT-enabled software twins.
- Detecting calibration drift in imaging devices by correlating IoT sensor data with DT benchmarks.

Graph 3 (Heatmap): Detection Likelihood of Failure modes: Traditional RCA vs DT-enable



Interpretation:

The heatmap reinforces that DTs provide predictive foresight into failure causes, reducing reliance on corrective actions after adverse events and thereby enhancing patient safety.

5.5 Credibility Assessment

The ultimate test for DT adoption in medical device RCA lies in regulatory credibility. Regulators demand computational evidence that is verified, validated, and uncertainty-quantified (Morrison et al. 2019; Freitas 2020).

Traditional RCA offers traceability of physical inspections but lacks rigor in uncertainty quantification and predictive validation. DTs, when properly validated, can provide transparent audit trails, simulation reproducibility, and quantified confidence intervals for predictions (Parvinian et al. 2019).

Graph 4 (Radar Chart): Credibility Assessment: Traditional RCA vs. DT-enabled RCA



Interpretation:

This analysis highlights that DT-enabled RCA is inherently more compatible with emerging regulatory paradigms, such as FDA's risk-based model credibility framework and EMA's openness to in silico trials.

6. Discussion

The integration of Digital Twins (DTs) into root cause analysis (RCA) in medical device manufacturing offers transformative potential but also introduces important challenges and regulatory considerations. This section discusses the benefits, limitations, regulatory alignment, and future opportunities of DT-enabled RCA, situating the discussion within both industrial practice and medical device compliance frameworks.

6.1 Benefits of DT-Enabled RCA

One of the most significant benefits of DT-enabled RCA lies in its enhanced detection accuracy. Traditional RCA approaches typically depend on retrospective analysis of production logs, manual inspections, and expert interpretation, which are prone to subjectivity and delayed resolution (Zema et al., 2015). In contrast, DTs integrate real-time sensor data with high-fidelity virtual models, allowing anomalies to be identified with far greater precision. Papacharalampopoulos et al. (2020) demonstrated how a DT-driven framework for analyzing production alarms in a smart factory could automate the identification of underlying root causes, thereby reducing diagnostic errors and shortening resolution times. Within the context of medical device manufacturing, this accuracy is especially critical, as even minor deviations in processes can have direct implications for patient safety and regulatory compliance.

Another clear advantage is the predictive and proactive capability of DT-enabled RCA. Instead of diagnosing failures after they occur, DTs allow for the anticipation of failures by simulating performance under various conditions and predicting degradation patterns. Tao et al. (2018) emphasized how DT-driven prognostics and health management (PHM) systems could be employed to forecast failure events and extend equipment lifespan. Applied to RCA, these predictive models empower manufacturers to simulate potential corrective actions, assess their outcomes virtually, and implement only the most effective measures. This proactive approach minimizes the risk of recurring failures, reduces downtime, and enhances overall operational efficiency.

Furthermore, DTs provide automated regulatory traceability, which addresses one of the most persistent challenges in the medical device industry: compliance documentation. Standards such as ISO 13485 emphasize traceability of design, manufacturing, and quality management processes (Bos, 2018). Traditionally, this has required labor-intensive record-keeping, creating inefficiencies and opportunities for human error. By embedding compliance requirements directly into DT frameworks, manufacturers can automatically log process data, corrective measures, and audit trails, generating real-time evidence for inspections and regulatory reviews. Such automation not only reduces administrative overhead but also ensures continuous compliance with global standards, offering regulators a more transparent view of product quality and safety.

6.2 Challenges and Limitations

Despite these advantages, DT-enabled RCA also presents notable challenges and limitations that must be carefully addressed before large-scale adoption in medical device manufacturing becomes feasible.

A critical concern is the issue of model validation and credibility. The effectiveness of DTs relies on their ability to faithfully replicate the physical systems they represent. Without robust validation protocols, DT models may generate misleading results, undermining confidence in RCA outcomes. Freitas (2020) emphasized the importance of verification, validation, and uncertainty quantification (VVUQ) in computational modeling, noting that inconsistencies in methodologies across industries limit the reliability of simulation-based evidence. In medical device contexts—where regulatory approval hinges on demonstrable reliability—the absence of standardized validation frameworks poses a significant barrier.

In addition, there exists considerable resistance to adoption in highly regulated environments. Medical device manufacturers operate under stringent oversight, with regulators emphasizing proven and transparent methodologies. Laukkarinen, Kuusinen, and Mikkonen (2017) reported that even agile and DevOps practices—widely accepted in other industries—encounter resistance in medical device software development due to compliance concerns. The introduction of DTs, which involve complex simulations and automated decision-making, may therefore be perceived as adding uncertainty rather than reducing it. Cultural inertia, fear of regulatory pushback, and the costs of system integration may discourage manufacturers from embracing DT-enabled RCA despite its potential benefits.

6.3 Integration with Regulatory Pathways

For DT-enabled RCA to achieve regulatory acceptance, it must align with established medical device standards and frameworks. ISO 13485 sets requirements for quality management systems, emphasizing risk management and traceability throughout the product lifecycle (Bos, 2018). DTs can complement ISO 13485 by embedding automated data collection and root cause documentation directly into digital models, thereby improving audit readiness and risk transparency. Similarly, EN 62304 outlines lifecycle requirements for medical device software, focusing on safety and reliability (Höss et al., 2014). DTs can be leveraged to simulate software behavior under diverse conditions, strengthening compliance with these requirements.

In the broader regulatory context, agencies such as the U.S. Food and Drug Administration (FDA) have begun acknowledging the role of computational evidence in supporting device approval. Morrison et al. (2019) proposed a risk-based framework for assessing the credibility of computational models, applying it to hemolysis simulations in blood pumps. Parvinian et al. (2019) similarly emphasized the need for structured credibility evidence in closed-loop control systems for critical care devices. Beyond these device-specific studies, Viceconti, Henney, and Morley-Fletcher (2016) highlighted the potential of in silico clinical trials, wherein computational models of patient populations are used to supplement or replace traditional clinical testing. Collectively, these developments suggest that regulators are increasingly open to computational evidence—provided that models are transparent, validated, and risk-based. For DT-enabled RCA, this evolving regulatory stance presents a pathway for eventual integration into formal submissions.

6.4 Future Outlook

Looking ahead, several emerging directions are poised to shape the role of DT-enabled RCA in medical device manufacturing.

First, the integration of artificial intelligence (AI) with DTs will enable a transition from predictive to prescriptive RCA. By embedding machine learning algorithms within DT frameworks, manufacturers can move beyond identifying potential failures to generating optimized corrective action plans in real time. These AI-enhanced DTs would continuously adapt to new data, improving RCA accuracy and responsiveness over time.

Second, the convergence of DT applications across industries will accelerate innovation in medical device contexts. For instance, DTs are increasingly applied in pharmaceutical and biopharmaceutical manufacturing to optimize production and ensure quality control (Chen et al., 2020). Lessons learned from these industries—particularly regarding process validation and large-scale data integration—can inform DT adoption in medical devices, creating opportunities for harmonized approaches across the life sciences sector.

Finally, the establishment of standardized validation protocols for DTs will be essential for regulatory trust and industry-wide adoption. Organizations such as ISO and IEEE, alongside regulatory agencies, are expected to formalize guidelines for DT verification, validation, and uncertainty quantification. Standardization will reduce variability in DT practices, facilitate regulatory review, and enable small and medium-sized enterprises (SMEs) to adopt DT-enabled RCA with greater confidence. Ultimately, such protocols will serve as the foundation for embedding DT-based evidence into routine regulatory submissions.

7. Conclusion

The findings of this study establish Digital Twins (DTs) as transformative enablers of faster, more accurate, and proactive root cause analysis (RCA) in complex medical device manufacturing. Traditional RCA processes in this sector have long suffered from reactive orientation, dependence on historical data, and a lack of dynamic feedback loops (Zema et al. 2015). These limitations often lead to delayed corrective actions and increased risks for patient safety. By contrast, DTs leverage real-time synchronization of physical assets with their virtual counterparts, enabling continuous monitoring, anomaly detection, and predictive simulation of failure modes before they manifest in physical systems (Grieves 2014; Boschert & Rosen 2016; Qi et al. 2018). This shift from retrospective to proactive RCA provides manufacturers with both speed and precision in identifying and addressing defects or process deviations.

A critical contribution of DT-enabled RCA lies in regulatory compliance and traceability. Medical device manufacturing is one of the most heavily regulated industries worldwide, requiring strict adherence to frameworks such as ISO 13485, which emphasizes quality management and risk control, and EN 62304, which governs medical device software development (Bos 2018; Höss et al. 2014). DT systems inherently generate comprehensive, automated audit trails, aligning with the regulatory requirements of traceability and transparency. Moreover, risk-based frameworks proposed by Morrison et al. (2019) and Parvinian et al. (2019) demonstrate that DTs can supply credibility evidence for computational models used in RCA, making them viable for regulatory approval processes. In this sense, DTs not only support operational efficiency but also act as compliance facilitators, ensuring that innovations in quality assurance remain within the boundaries of established standards.

Beyond compliance, DT-enabled RCA contributes significantly to operational efficiency and patient safety. By minimizing downtime through predictive analytics and enabling earlier identification of root causes, DTs reduce the occurrence of defective products entering the market (Tao et al. 2018; Papacharalampopoulos et al. 2020). This aligns with the broader goals of Industry 4.0 and smart manufacturing, where cyber–physical systems and IoT-driven intelligence improve both process reliability and responsiveness (Tao et al. 2019). In practical terms, enhanced RCA ensures that devices such as blood pumps, imaging systems, and implantable products undergo more rigorous virtual testing environments, thereby safeguarding patient outcomes (Morrison et al. 2019; Viceconti et al. 2016).

Despite these advantages, challenges remain in terms of model validation and regulatory integration. Verification, validation, and uncertainty quantification (VVUQ) frameworks are still maturing, and regulatory authorities require robust, standardized methods for evaluating the reliability of DT-driven RCA outcomes (Freitas 2020). Without consistent validation protocols, there is a risk that DT systems may be perceived as “black box” solutions, reducing regulatory and industry trust. As highlighted by Laukkarinen et al. (2017), resistance to adopting new methodologies is particularly strong in regulated environments, further underscoring the need for consensus-driven guidelines to ensure the safe and standardized deployment of DT-enabled RCA.

Looking ahead, the future role of AI and interoperability within DT ecosystems is poised to accelerate their adoption in medical device manufacturing. AI-driven analytics can transform DTs from predictive tools into prescriptive RCA systems, where not only are root causes identified, but optimal corrective actions are also recommended in real time (Tao et al. 2018). Interoperability will also play a key role: as manufacturing ecosystems increasingly involve multi-device and multi-vendor environments, DT platforms must seamlessly integrate across the supply chain, production floor, and post-market surveillance systems (Lim et al. 2020; Chen et al. 2020). The convergence of DT, AI, and in silico clinical trials will further expand their relevance, allowing manufacturers and regulators to test interventions virtually before patient exposure (Viceconti et al. 2016).

In conclusion, DTs represent a paradigm shift in RCA practices for medical device manufacturing. They provide manufacturers with unmatched speed, accuracy, and compliance-readiness, while contributing directly to patient safety and global regulatory confidence. However, achieving their full potential will require collaborative efforts to establish validation standards, foster regulatory acceptance, and promote AI-enhanced, interoperable DT ecosystems. When these challenges are addressed, DTs will not only optimize RCA but also underpin the future of resilient, intelligent, and trustworthy medical device manufacturing.

References

1. Boschert, S., & Rosen, R. (2016). Digital twin—the simulation aspect. In *Mechatronic futures: Challenges and solutions for mechatronic systems and their designers* (pp. 59-74). Cham: Springer International Publishing.

2. Grieves, M. (2014). Digital twin: manufacturing excellence through virtual factory replication. *White paper*, *1*(2014), 1-7.
3. Kritzinger, W., Karner, M., Traar, G., Henjes, J., & Sihn, W. (2018). Digital Twin in manufacturing: A categorical literature review and classification. *Ifac-PapersOnline*, *51*(11), 1016-1022.
4. Qi, Q., Tao, F., Zuo, Y., & Zhao, D. (2018). Digital twin service towards smart manufacturing. *Procedia Cirp*, *72*, 237-242.
5. Tao, F., Qi, Q., Wang, L., & Nee, A. Y. C. (2019). Digital twins and cyber–physical systems toward smart manufacturing and industry 4.0: Correlation and comparison. *Engineering*, *5*(4), 653-661.
6. Lim, K. Y. H., Zheng, P., & Chen, C. H. (2020). A state-of-the-art survey of Digital Twin: techniques, engineering product lifecycle management and business innovation perspectives. *Journal of intelligent manufacturing*, *31*(6), 1313-1337.
7. Rosen, R., Von Wichert, G., Lo, G., & Bettenhausen, K. D. (2015). About the importance of autonomy and digital twins for the future of manufacturing. *Ifac-papersonline*, *48*(3), 567-572.
8. Ma, X., Tao, F., Zhang, M., Wang, T., & Zuo, Y. (2019). Digital twin enhanced human-machine interaction in product lifecycle. *Procedia Cirp*, *83*, 789-793.
9. Papacharalampopoulos, A., Giannoulis, C., Stavropoulos, P., & Mourtzis, D. (2020). A digital twin for automated root-cause search of production alarms based on KPIs aggregated from IoT. *Applied Sciences*, *10*(7), 2377.
10. Zhang, C., Xu, W., Liu, J., Liu, Z., Zhou, Z., & Pham, D. T. (2019). A reconfigurable modeling approach for digital twin-based manufacturing system. *Procedia Cirp*, *83*, 118-125.
11. Tao, F., Zhang, M., Liu, Y., & Nee, A. Y. (2018). Digital twin driven prognostics and health management for complex equipment. *Cirp Annals*, *67*(1), 169-172.
12. Bos, G. (2018). ISO 13485: 2003/2016—medical devices—quality management systems—requirements for regulatory purposes. In *Handbook of Medical Device Regulatory Affairs in Asia* (pp. 153-174). Jenny Stanford Publishing.
13. Parvinian, B., Pathmanathan, P., Daluwatte, C., Yaghouby, F., Gray, R. A., Weininger, S., ... & Scully, C. G. (2019). Credibility evidence for computational patient models used in the development of physiological closed-loop controlled devices for critical care medicine. *Frontiers in physiology*, *10*, 220.
14. Morrison, T. M., Hariharan, P., Funkhouser, C. M., Afshari, P., Goodin, M., & Horner, M. (2019). Assessing computational model credibility using a risk-based framework: application to hemolysis in centrifugal blood pumps. *Asaio Journal*, *65*(4), 349-360.
15. Freitas, C. J. (2020). Standards and methods for verification, validation, and uncertainty assessments in modeling and simulation. *Journal of Verification, Validation and Uncertainty Quantification*, *5*(2), 021001.
16. Zema, M., Rosati, S., Gioia, V., Knaflitz, M., & Balestra, G. (2015, August). Developing medical device software in compliance with regulations. In *2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)* (pp. 1331-1334). IEEE.
17. Laukkarinen, T., Kuusinen, K., & Mikkonen, T. (2017, May). DevOps in regulated software development: case medical devices. In *2017 IEEE/ACM 39th International Conference on Software Engineering: New Ideas and Emerging Technologies Results Track (ICSE-NIER)* (pp. 15-18). IEEE.
18. Höss, A., Lampe, C., Panse, R., Ackermann, B., Naumann, J., & Jäkel, O. (2014). First experiences with the implementation of the European standard EN 62304 on medical device software for the quality assurance of a radiotherapy unit. *Radiation Oncology*, *9*(1), 79.
19. Viceconti, M., Henney, A., & Morley-Fletcher, E. (2016). In silico clinical trials: how computer simulation will transform the biomedical industry. *International Journal of Clinical Trials*, *3*(2), 37-46.

20. Chen, Y., Yang, O., Sampat, C., Bhalode, P., Ramachandran, R., & Ierapetritou, M. (2020). Digital twins in pharmaceutical and biopharmaceutical manufacturing: a literature review. *Processes*, *8*(9), 1088.